论文部分内容阅读
目的观察醒脑静注射液治疗脓毒症相关脑病的临床效果。方法收集脓毒症相关脑病患者60例,随机分为对照组和试验组各30例。对照组按照2012脓毒症指南给予治疗,试验组在此基础上加用醒脑静注射液静脉滴注。治疗7天,观察2组治疗前后体温、血象、APACHE II评分、GCS评分、BIS结果,以及28天死亡率。结果治疗后,2组的APACHE II评分均降低,GCS评分及BIS检查均有改善(P<0.05);试验组APACHE II评分、GCS评分、BIS等指标较对照组改善明显(P<0.05),试验组死亡率低于对照组(P<0.05),且没有发现醒脑静注射液相关不良反应。结论醒脑静注射液治疗脓毒症相关脑病安全有效,可降低死亡率。
Objective To observe the clinical effect of xingnaojing injection in treating sepsis-related encephalopathy. Methods Sixty patients with sepsis-related encephalopathy were collected and randomly divided into control group and experimental group of 30 patients. The control group according to the 2012 sepsis guidelines for treatment, the experimental group on this basis plus Xingnaojing injection intravenous drip. After 7 days of treatment, body temperature, hemogram, APACHE II score, GCS score, BIS result, and 28-day mortality were observed before and after treatment. Results After treatment, the scores of APACHE II decreased, GCS scores and BIS improved (P <0.05). The scores of APACHE II, GCS and BIS in the experimental group were significantly improved than those in the control group (P <0.05) Mortality in the experimental group was lower than that in the control group (P <0.05), and no adverse reactions associated with XNX were found. Conclusion Xingnaojing injection is safe and effective in treating sepsis-related encephalopathy and can reduce mortality.